CORO1C expression levels were positively related with lymphatic metastasis (82.7%), and higher clinical stage gastric cancer patients (80.8%) tended to express more CORO1C than lower clinical stage gastric cancer patients (57.1%), showing that poor clinicopathological parameters, including lymph node metastasis and clinical stage, were associated with the high levels of CORO1C in gastric cancer patients. The gene discussed is CORO1C; the disease is metastatic malignant neoplasm in the lymph nodes.